https://www.zacks.com/stock/news/2234513/gear-up-for-korn-ferry-kfy-q3-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2234513
Mar 01, 2024 - Beyond analysts' top -and-bottom-line estimates for Korn/Ferry (KFY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended January 2024.
zc:4420499407625679835
0
https://www.zacks.com/stock/news/2234514/gear-up-for-rev-group-revg-q1-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2234514
Mar 01, 2024 - Evaluate the expected performance of REV Group (REVG) for the quarter ended January 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zc:-6036178931026224390
0
https://www.rttnews.com/story.aspx?Id=3429102
Mar 01, 2024 - Old Republic International Corp. (ORI), an insurance company, announced on Friday that its Board has authorized a $1.10 billion share repurchase program.
0
rttnews:7072194401046335977
0
https://seekingalpha.com/article/4675131-schrodinger-q4-earnings-conservative-guidance-sets-stock-up-for-solid-2024-reiterate-hold?source=feed_all_articles
Feb 29, 2024 - Schrodinger's Q4'23 results were strong, but weak guidance for 2024 caused a drop in share price. See why we are neutral on SDGR stock.
0
sa:6391335390916408915
0
https://www.startribune.com/patent-medtronic-axonics-boston-scientific-neurostimulator-interstim-bladder-bowl-control/600347191/
Feb 29, 2024 - The legal dispute with Axonics about the InterStim product started more than four years ago.
0
sb:7196029108071754574
0
https://www.cnbc.com/2024/02/29/pce-inflation-january-2023-.html
Feb 29, 2024 - The core PCE price index was expected to increase 0.4% in January on a monthly basis and 2.8% from a year ago.
0
cnbc:6467149747370699572
0
https://www.zacks.com/stock/news/2234137/sarepta-srpt-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234137
Feb 29, 2024 - Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
zc:-2192800226062534333
0
https://www.zacks.com/stock/news/2234118/catalyst-cprx-q4-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2234118
Feb 29, 2024 - Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
zc:6660098082278326381
0
https://www.zacks.com/stock/news/2234117/accel-acel-q4-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234117
Feb 29, 2024 - Accel's (ACEL) fourth-quarter 2023 results reflect growth in the number of locations and gaming terminals, contributing to the top-line growth. Also, its focus on the local gaming market bodes well.
zc:-4996260003472887159
0